Inhibiting costimulatory activation of T cells: A viable treatment option for rheumatoid arthritis?

Drugs

Volumn 67, Issue 1, 2007, Pages 1-9

  Pollard, Louise C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B7 ANTIGEN; BELATACEPT; BIOLOGICAL RESPONSE MODIFIER; CD28 ANTIGEN; CD86 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ADD ON THERAPY; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANXIETY; BACTERIAL ARTHRITIS; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FATALITY; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HEART INFARCTION; HUMAN; IMMUNOMODULATION; INFECTION; LUPUS VULGARIS; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; OPPORTUNISTIC INFECTION; PATHOGENESIS; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SYNOVITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES;

EID: 33846233931     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767010-00001     Document Type: Review

References (30)

1. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003; 426 (6965): 454-60
2. Mima T, Saeki Y, Ohshima S, et al. Transfer of rheumatoid arthritis into severe combined immunodeficient mice: the pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints. J Clin Invest 1995; 96 (4): 1746-58
3. Steiner G, Tohidast-Akrad M, Witzmann G, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 1999; 38 (3): 202-13
4. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344 (12): 907-16
5. VanderBorght A, Geusens P, Raus J, et al. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum 2001; 31 (3): 160-75
6. Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21: 305-34
7. Janeway Jr CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76 (2): 275-85
8. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58
9. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1 (5): 405-13
10. Wang XB, Zheng CY, Giscombe R, et al. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol 2001; 54 (5): 453-8
11. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183 (6): 2541-50
12. Simmonds MJ, Gough SC. Genetic insights into disease mechanisms of autoimmunity. Br Med Bull 2005; 71: 93-113
13. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-9
14. Nadler S, Townsend R, Mikesell G, et al. Abatacept (CTLA4Ig; BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations [abstract no. THU0103]. Ann Rheum Dis 2004; 63 Suppl. 1: 142
15. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46 (6): 1470-9
16. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
17. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349 (20): 1907-15
18. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial [published erratum appears in Arthritis Rheum 2005 Oct; 52 (10): 3321]. Arthritis Rheum 2005; 52 (8): 2263-71
19. Ware JE. The SF-36 health survey. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Lippincott-Raven: Philadelphia, 1996
20. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006 Apr; 33 (4): 681-9
21. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002 Mar; 21 (2): 271-92
22. Dougados M, Westhovens R, St Clair E, et al. Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract no. 359]. Arthritis Rheum 2004; 50: S185
23. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353 (11): 1114-23
24. Fries JF, Spitz PW, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45
25. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006 Oct; 45 (10): 1238-46
26. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006 Jun 20; 144 (12): 865-76
27. Genant HK, Jiang Y, Peterfy C, et al. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998 Sep; 41 (9): 1583-90
28. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104
29. Moreland L, Kaine J, Espinoza L, et al. Safety of abatacept in rheumatoid arthritis patients in five double-blind, placebo-controlled trials [abstract no. 886]. Arthritis Rheum 2005; 52: S350
30. Combe B, Weinblatt M, Birbara C, et al. Safety and patient-reported outcomes associated with abatacept in the treatment of rheumatoid arthritis patients receiving background disease modifying anti-rheumatic drugs (DMARDs): the ASSURE trial [abstract no. 1918]. Arthritis Rheum 2005; 52: S709